Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -0.28%67 Future 3-5Y EPS without NRI Growth Rate is 4.18 as of Sep. 06, 2026. GuruFocus rates CSLLY with a GF Score™ of 67/100 and a GF Value™ of $47.52 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 411 Biotechnology companies, CSL ranks worse than 76.64% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, CSL's Future 3-5Y EPS without NRI Growth Rate is 4.18.
CSL (OTCPK:CSLLY) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
CSL Future 3-5Y EPS without NRI Growth Rate Related Terms
CSLLY vs VRTX, REGN, MRNA: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, CSL's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CSL's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 4.18 mean?
CSL (CSLLY) has a Future 3-5Y EPS without NRI Growth Rate of 4.18 as of Sep. 06, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for CSL and its competitors. According to the industry distribution chart, CSL ranks #315 out of 411 companies in the Biotechnology industry, placing it in the top 76.6%.
Is CSL's Future 3-5Y EPS without NRI Growth Rate too high?
CSL's current Future 3-5Y EPS without NRI Growth Rate is 4.18. The Biotechnology industry median Future 3-5Y EPS without NRI Growth Rate is 21.97. CSL's value of 4.18 is 81% below this industry median. Based on the distribution chart, CSL ranks #315 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Future 3-5Y EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #315 out of 411 companies for Future 3-5Y EPS without NRI Growth Rate. This places CSL in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 21.97. CSL's value of 4.18 is 81% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Biotechnology company?
The median Future 3-5Y EPS without NRI Growth Rate among Biotechnology companies is 21.97, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Future 3-5Y EPS without NRI Growth Rate of 4.18 is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for CSL and its competitors. For the Biotechnology industry, the median Future 3-5Y EPS without NRI Growth Rate is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Future 3-5Y EPS without NRI Growth Rate is 4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.52, compared to a current price of $31.61 — trading 33.5% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 4.18 and 81% below the Biotechnology industry median of 21.97. CSL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current Future 3-5Y EPS without NRI Growth Rate is 4.18 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $31.61 is trading 33.5% below its estimated GF Value™ of $47.52.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Future 3-5Y EPS without NRI Growth Rate: 4.18
GF Value™: $47.52 vs. price of $31.61 (33.5% below fair value)
Industry Position: 81% below the Biotechnology median (#315 of 411)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
67GF Score
Get the complete analysis for CSLLY
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
